FDA's interim peptide compounding policy goes to the White House for review
The Briefing, October 25, 2026. This week in peptides, in plain English.
Vol. 1 · Issue 05October 25, 2026
A draft peptide compounding policy reaches the White House as a safety group petitions against it, plus a Phase III tirzepatide combination trial and semaglutide in cannabis use disorder.
Regulation · Lead
An interim peptide compounding policy goes to the White House, and a safety group pushes back
On October 14, HHS and the FDA sent a document titled the Interim Access Policy for Compounding Using Certain Peptides to the White House Office of Management and Budget (OMB) for review, STAT reported. According to STAT, the policy would likely let state-licensed 503A pharmacies compound some restricted peptides without FDA enforcement while formal rules are written.
This is the first concrete step behind the temporary plan the Washington Post described earlier this month, which at the time rested on two unnamed sources.
A week later, on October 21, the Partnership for Safe Medicines filed a citizen petition pushing the other way. It asks the FDA to block compounding of unapproved and poorly characterised peptides. It also asks the agency to set aside the July advisory committee vote, which the group says was compromised by conflicts of interest.
What it means: the policy now exists as a real document inside government, not just a reported draft. But it is under review, not in force. Its text and its list of peptides are not public, so nobody outside government can say which compounds it covers, and it could still change before release.
What it does not mean: no peptide has been added to the 503A bulks list, and nothing has been approved. As STAT describes it, the policy would relax enforcement for some compounding while rules are written, which is different from declaring any peptide safe or effective. The petition is a request to the FDA, not a ruling. For what is known about individual compounds, see the dossier pages.
A Phase III trial will test tirzepatide combined with eloralintide in one formulation
A new Phase III trial registered on October 19 will test a coformulation of tirzepatide and a second investigational compound, eloralintide, under the name EloraTZP. It will enrol adults with obesity who do not have type 2 diabetes, and participation is expected to last about two years. It is not yet recruiting.
The design compares four groups: the combination, tirzepatide alone, eloralintide alone, and placebo. The main questions are efficacy and safety for body weight reduction.
What it means: a four-arm design is the clean way to answer whether a combination does more than either ingredient on its own, rather than simply more than nothing. Phase III is the late stage of testing that typically comes before a company seeks approval. The registry entry does not describe how eloralintide works, so we will not guess here.
What it does not mean: there are no results yet, and the trial has not started enrolling. The combination is investigational. Background on tirzepatide is on its dossier page.
A small pilot study will look at semaglutide and cannabis cravings in the brain
A Phase II pilot study registered on October 19 will give semaglutide to adults with cannabis use disorder and look at how their brains react to cannabis-related cues. Participants will have weekly injections over eight weeks, five in-person visits across nine weeks, and fMRI brain scans at two of those visits. It is not yet recruiting.
The study asks two questions: does semaglutide change reactivity to cannabis cues, and can it safely reduce how often people use cannabis.
What it means: researchers are testing whether a drug known for appetite and weight might also touch the brain's response to other cues. That idea is a hypothesis being explored, not an established effect. A pilot like this is meant to show whether a bigger study is worth running.
What it does not mean: semaglutide is not a treatment for cannabis use disorder. Every participant receives the drug, so there is no placebo group to compare against, which limits what the results can show. Treat any early findings as a signal, not proof. More on semaglutide is on its dossier page.
In focus: why PT-141 is used as needed, not on a schedule
PT-141, also called bremelanotide, is one of the few peptides in our guide with a clear regulatory status: an FDA-approved formulation, Vyleesi, is used to treat acquired, generalised hypoactive sexual desire disorder in certain premenopausal women. Other uses, including in men, are off-label.
Its rhythm follows from how it works. PT-141 activates melanocortin receptors in the brain, mainly MC4R, which are involved in sexual motivation. That is a different route from drugs like sildenafil, which act on blood flow. PT-141 is aimed at desire rather than mechanics, so it is used around the occasions where that matters rather than built up day after day like a weekly weight-loss peptide.
That is why its run is described as as needed, not on a schedule. The approved label also sets a ceiling on frequency: no more than once in 24 hours. Exact amounts are a matter for a prescriber and the label, and our dossier page sets out what the approved product specifies.
The frequency limit makes sense next to the side effects. Nausea is the most common, along with flushing and headache. PT-141 can briefly raise blood pressure, so it is not for anyone with uncontrolled high blood pressure or heart disease. Darkening of the skin has been reported with frequent use, another reason more often is not better.
On evidence, the approval rests on phase 3 trials called RECONNECT in premenopausal women with low desire. That is solid for that group. For other groups, the evidence is thinner, which is what off-label means in practice. Full detail is on the PT-141 dossier: https://jointhedailystack.com/peptides/pt-141/